Anthera (ANTH) Strengthens Senior Management With President/COO & Chief Technology Officer – Craig Thompson is joining ANTH as President and Chief Operating Officer. He comes with an experienced Big Pharma strategic marketing background (~10 years at Merck, ~8 at Pfizer), and will oversee both of the Company’s late-stage development programs and commercial preparation efforts. read more…
BIOINVEST BREAKING NEWS – Special Update – Anthera (ANTH) – Ending Japanese Deal Is No Big Deal; All B-Mod/Sollpura Programs/Timelines Unchanged – Reiterate BUY – Despite helping financially when ANTH needed the funds last year, no Wall Street models included a Japanese approval for IgAN. The receipt of a termination notice from its development partner in Japan, Zenyaku, was “at will” and alleged no breach of the License Agreement by Anthera. read more…
After the successful completion of two interim looks at the Phase III trials for blisibimod, we spoke with Anthera Chief Medical Officer Colin Hislop M.D. to further delve into the CHABLIS study design. After performing further due diligence, we remain confident in b-mod’s clinical potential and believe that the odds of success are much greater than they were in PEARL.
Anthera announced last week that they priced a public offering of 60 million shares at $0.66 per share, which will add $40 million to their balance sheet. Jefferies is acting as sole book-running manager in the offering and Leerink Swann is acting as co-manager. These are quality investment banks and it is an impressive accomplishment for […]
Anthera has switched gears as they recently disclosed that development program testing blisibimod in lupus is on hold as the company searches for a partner that will fund further development. This is a disappointment as ANTH had previously planned to start Phase III development for lupus this year. ANTH now says that that they are […]
Anthera’s CFO and Chief Medical Officer explained the detailed plans for the blisibimod (B-mod) Phase III program at the recent Piper Jaffray conference. The Phase III development program was blessed by the FDA in September and the EU regulatory agency in April. The first Phase III – CHABLIS1 will start where PEARL was done – Asia/Pacific/S. […]
Anthera’s stock is down sharply since the last Issue. It appears that the company had been out trying to put together a private financing but could not execute the transaction. Hurricane Sandy made it almost impossible to conduct business normally and ANTH was not able to close a transaction. Alternatively, ANTH entered into an At Market […]
Anthera’s stock is up since the last Issue as they have had two encouraging announcements. The most important was this week when they announced that an abstract from the Phase 2b PEARL-SC clinical study examining the treatment effect of blisibimod in systemic lupus patients has been accepted as a Late-Breaking poster presentation at the 2012 Annual […]